GoldenGolden
Advanced Search
OrbiMed

OrbiMed

U.S-based venture capital and private equity firm investing on life sciences companies worldwide.

OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San Francisco, California; Mumbai, India; Shanghai, China; Herzliya, Israel and Hong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Funding

OrbiMed focuses on funding companies in the field of life sciences. The firm invests globally, with past investments on companies based in North America, Europe, and Asia (China, India, and Israel). The firm finances companies at various stages of development, from seed to buyouts. Its most recent funding round raised $551 million on September 2017.

OrbiMed is a healthcare fund management company based in New York City. Founded in 1989, the firm focuses on investing in life sciences and healthcare industries.

The firm invests as private equity, public equity and private credit/royalty. OrbiMedi globally invests from seed-stage venture to large corporations.

Notable interests of the firm include gene therapy, immuno-therapy and gene editing, etc.

As of November 2019, the firm has invested in MDClone, Adicet Bio, Cleave Therapeutics, Edgewise Therapeutics, GrayBug, ORIC Pharmaceuticals, Passage Bio, PMV Pharmaceuticals, Protekt Therapeutics and Repare Therapeutics, etc.

Timeline

March 1, 2021
OrbiMed banks $3.5 billion in its latest raise, a sum that will be divided among three private investment funds, including one focused on early-stage companies in North America and Europe and a second aimed at companies of various stages in Asia.
1989
Founded

Invested in

Patents

Products

Funding Rounds Participated In

People

Name
Role
LinkedIn

Carl Gordon

Managing Partner

Carter Neild

General Partner

Chau Knuong

Partner

David Wang

Partner

Geoffrey Hsu

General Partner

...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

MDClone

Adaptimmune

Biopharmaceuticals

Adicet Bio

Adicet Bio

Biopharmaceuticals

Adimab

Biopharmaceuticals

...

News

Title
Author
Date
Publisher
Description
Emmy Lucas
September 10, 2021
FierceBiotech
OrbiMed Advisors and Lilly Asia Ventures are two key players pouring money into RNA-targeting technology via ADARx Pharmaceuticals' $75 million series B round. The funding will take the San Diego-based biotech's growing pipeline of RNA-targeting therapeutics into the clinic, ADARx said in a statement on Wednesday.
binx health, inc
May 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people...
Alex Keown
May 26, 2021
BioSpace
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
Ben Adams
May 12, 2021
FierceBiotech
OrbiMed's executive partner and a founder of rare disease biopharma Alexion (now AstraZeneca), Stephen Squinto, Ph.D., is taking the reins at non-viral gene therapy biotech Gennao Bio.
i2020 Accelerator
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced multiple start-up and...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.